

***Company Information and Disclosure Statement***  
***Section One: Issuers' Quarterly Disclosure Obligations for***  
***the Period Ended September 30, 2014***

**SOLOS ENDOSCOPY, INC.**

**OTCPK: SNDY**

# OTC Pink Basic Disclosure Guidelines

## 1) Name of the issuer and its predecessors (if any)

Exact Company Name: Solos Endoscopy, Inc. (hereinafter referred to as “we”, “us”, or “our” or “the Issuer”).

Name used by predecessor entities in the past five years:

- a) Formerly=ViaDux Health, Inc. until 3-06
- b) Formerly=Prime Capital Resources, Inc. until 9-16-05. State of Incorporation Florida changed to Nevada concurrent with name change
- c) Formerly=MobileVest, Inc. until 8-02

## 2) Address of the issuer's principal executive offices

### Company Headquarters

65 Sprague Street, West B  
Boston, MA 02136  
Phone: 617-360-9700  
Fax: 617-360-9740  
Website: [www.solosendoscopy.com](http://www.solosendoscopy.com)

### IR Contact

Solos Endoscopy, Inc.  
65 Sprague Street, West B  
Boston, MA 02136  
Phone: 617-360-9719

## 3) Security Information

Trading Symbol: SNDY

Common Stock Outstanding: 1,749,488,055 (as of 09/30/2014)

Restricted Common Stock: 15,971,488 (as of 09/30/2014)

Preferred Stock Outstanding: 508,629<sup>(1)</sup> (as of 09/30/2014)

CUSIP Number: 834371403

Par or Stated Value: Both common and preferred stock is at \$0.001

Total shares authorized: Common - Two Billion Nine Hundred Million (2,900,000,000) shares. Preferred - Ten million (10,000,000) shares as of September 30, 2014.

Total shares outstanding: 1,749,996,684<sup>(1)</sup> (as of 09/30/2014)

<sup>(1)</sup>On February 9, 2012, Fred Schiemann retired 15,000,000 shares of Common Stock held in her name in exchange for 11,794 Preferred Series B Shares of Solos Endoscopy. The shares are outstanding on the books of the Company, but have not been issued by the Transfer Agent to date.

### Transfer Agent:

Pacific Stock Transfer  
4045 South Spencer Street, Ste. 403  
Las Vegas, NV 89119  
702-361-3033

Registered Under Exchange Act: Yes

Regulatory Authority: Security Exchange Commission (SEC)

List any restrictions on the transfer of security:

N/A

Describe any trading suspension orders issued by the SEC in the past 12 months:

N/A

#### 4) Issuance History

- A. The nature of each offering (e.g., Securities Act Rule 504, interstate, etc.);
- B. Any jurisdiction where the offering was registered or qualified;
- C. The number of shares offered;
- D. The number of shares sold;
- E. The price at which the shares were offered, and the amount actually paid to the issuer;
- F. The trading status of the shares; and
- G. Whether the certificates or other documents that evidence the shares contain legend (1) stating that the shares have registered under the Securities Act (2) setting forth or referring to the restrictions on transferability and sales of the share under the Securities Act.

Shareholder	Jurisdiction	Date	# of Shares Issued	Price Per share	Dollar Amount Sold	Nature of Offering
Boost Marketing LLC	Florida	06/19/2014	40,000,000	N/A	N/A	Conversion of Preferred B – Rule 144
Boost Marketing LLC	Florida	07/08/2014	30,000,000	N/A	N/A	Conversion of Preferred B – Rule 144
Boost Marketing LLC	Florida	07/14/2014	500	\$10.00	\$5,000	Preferred B Private Offering
Boost Marketing LLC	Florida	07/14/2014	350	\$10.00	\$3,500	Preferred B Private Offering
Boost Marketing LLC	Florida	07/25/2014	62,500,000	N/A	N/A	Conversion of Preferred B – Rule 144
Boost Marketing LLC	Florida	07/25/2014	500	\$10.00	\$5,000	Preferred B Private Offering
Boost Marketing LLC	Florida	07/25/2014	500	\$10.00	\$5,000	Preferred B Private Offering
Boost Marketing LLC	Florida	08/12/2014	58,333,333	N/A	N/A	Conversion of Preferred B – Rule 144
Boost Marketing LLC	Florida	08/12/2014	2,785	\$10.00	\$11,137	Debt Sale Agreement
Boost Marketing LLC	Florida	08/12/2014	500	\$10.00	\$5,000	Preferred B Private Offering
Boost Marketing LLC	Florida	08/28/2014	59,999,999	N/A	N/A	Conversion of Preferred B – Rule 144
Boost Marketing LLC	Florida	08/30/2014	700	\$10.00	\$7,000	Preferred B Private Offering
Boost Marketing LLC	Florida	09/18/2014	50,000,000	N/A	N/A	Conversion of Preferred B – Rule 144

*With respect to private offering of securities, the list shall also indicate the identity of the person who purchased securities in such private offering; provided, however, that in the event that any such person is an entity, the list shall also indicate (a) the identity of each natural person beneficially owning, directly or indirectly, more than ten percent (10%) of any class of equity securities of such entity and (b) to the extent*

*not otherwise disclosed, the identity of each natural person who controlled or directed, directly or indirectly, the purchase of such securities for such entity.*

## **5) Financial Statements**

The Company's Financial Statements, inclusive of items described below, for the period ended September 30, 2014 have been posted to the OTC Market's website.

*Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualifications for the OTC Pink Current Information tier. For the initial disclosure statements (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.*

- A. Balance sheet;
- B. Statement of income;
- C. Statement of cash flows;
- D. Financial note; and
- E. Audit letter, if audited

*The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.*

*You may either (i) attach/append the financial statements to this disclosure statements or (ii) post such financial statements through the OTC Disclosure & News Service as separate reporting using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Reports").*

*If you choose to publish the financial reports separately as described in part (ii) above, you must state in the accompanying disclosure statements that such financial statements are incorporated by reference.*

*Information contain in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports with 45 days of its fiscal quarter-end date.*

## **6) Describe the Issuer's Business, Products and Services**

*Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:*

- A. a description of the issuer's business operations;

Solos Endoscopy, Inc. is a 25+ year old healthcare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions.

- B. Date and State (or Jurisdiction) of Incorporation:

The Company was originally incorporated in 1986, in the State of Florida; the Company, as of February 2, 2005, is currently domiciled in the State of Nevada.

- C. the issuer's primary and secondary SIC codes;

Primary Code: 3841 - Surgical and Medical Instruments and Apparatus.  
Secondary Code: 5047 - Medical, Dental, and Hospital Equipment and Supplies.

D. the issuer's fiscal year end date;

December 31

E. principal products or services, and their markets;

Solos Endoscopy, Inc. is a provider of quality innovative healthcare instruments to hospitals across the United States. Solos Endoscopy is a healthcare technology company that develops and markets technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. The Company has several dozen products, mainly rigid endoscopes, hand held surgical instruments and video equipment for the minimally invasive surgery market, all of which can be found on its website at: [www.solosendoscopy.com](http://www.solosendoscopy.com). The Company markets its FDA approved products to hospitals, surgery centers, and physician offices.

Solos Endoscopy has received its ISO 13485:2003 Certification from TUV SUD America. The Certification to ISO 13485:2003 will in turn allow Solos Endoscopy to place the CE Mark on the majority of its endoscopic instruments including the MammoView® devices. The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada. The Certification came at the conclusion of a lengthy Audit with TUV SUD America in 2013. The Audit included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282).

### **Target Markets**

#### **The Women's Health Opportunity**

Women's healthcare products represent a major, dynamic, and rapidly growing market in the U.S. Factors driving this market include the aging of the female population, accompanied by advances in medical treatments for conditions that affect adult women of all ages. This has resulted in greatly increased demand for healthcare products for the early detection and treat of breast cancer, as well as, the management of benign uterine conditions, contraception, incontinence, infertility, and osteoporosis.

Consider the following facts about the U.S. healthcare market:

- Women make over 75% of the healthcare decisions in U.S. households
- Women spend almost two of every three healthcare dollars.
- Women also make more than 62% of physician visits in the United States
- Women make 60% of prescription drug purchases
- Women compose 75% of the nursing home population.

## **The Breast Cancer Challenge**

**A significant number of women are at risk, and the risk is growing.** One in eight women will develop breast cancer in her lifetime. This year 220,000 women in the United States alone will be diagnosed with breast cancer and 43,000 will die from the disease. Breast cancer is the second leading cause of death in American women of all ages. For women aged 25-55, it is the leading cause of death. The incidence of breast cancer has more than doubled over the past 30 years, and the prevalence continues to grow. Because of demographic and other trends, the number of women judged by the respected GAIL Model to be at high risk to develop breast cancer is expected to nearly double over the next 20 years—from approximately 8 million U.S. women today to nearly 15 million by 2020. The trends in Europe and Asia are similar.

**The promise of Endoscopic Breast Care.** Medical researchers have long recognized that nearly all breast cancer originates in the epithelial lining of the mammary duct system. Furthermore, it is well established that, in its early stages, most breast cancer develops very slowly and remains confined to the mammary ducts for a long time. If these very early stages of precancerous cells known as atypical ductal hyperplasia (ADH) and other early forms of cancer could be detected and treated while within the mammary duct system, this would result in substantially better treatment outcomes: very high survivability, avoidance of chemotherapy and radiation and much better breast conservation.

Solos Endoscopy currently has products and development projects underway that will advance this market with the improvement of new small diameter microendoscopes coupled with Solos' imaging technology. The result will be large, clear and sharp video images of the mammary duct system, with unprecedented perception and resolution. The images here, of a normal duct and precancerous changes (typically ADH), are examples of images during mammary ductoscopy procedures.

### **MammoView®**

Solos Endoscopy is developing its next generation breast endoscopy system – MammoView®. The MammoView® System includes a new family of endoscopes as well as related instrumentation and supplies. This product line brings several important advantages, including lower production costs, significantly lower price-per-procedure to customers, expanded intellectual property barriers to entry by competitors and the ability to facilitate a far broader range of breast cancer treatment methodologies and technologies.

### **Current Product Line Opportunity**

Solos Endoscopy offers “state of the art” medical grade video cameras, endocouplers, light sources, and instrumentation for the general surgical endoscopic market. These products are distributed or sold to the minimally invasive endoscopic market including, but not limited to general surgery and the growing office surgery market. In addition, Solos has manufactured, to its own design specifications, a complete line of branded laparoscopic instruments which compliment its video products for the general surgical market. In order to offer the market a one stop shopping option, Solos sells a full line of accessory items such as video carts, monitors, and printers. All Solos products are maintained by a full service repair department. This department is capable of repairing not only Solos branded products but also most competitors' video and instrument products. This allows Solos to provide the highest quality of service and products to its customers.

In addition to standard video equipment, Solos has focused on providing additional products that fill the requirements of all general surgical procedures. Solos offers a full line of instrumentation manufactured to its own specifications, including;

- Tissue forceps, graspers, clamps
- Dissector forceps
- Cannulas & Trocars
- Suction/Irrigation instruments
- Endoscopes

Additional information about Solos Endoscopy and its products can be found on the Company's website at [www.solosendoscopy.com](http://www.solosendoscopy.com).

## **7) Describe the Issuer's Facilities**

*The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.*

*In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.*

*If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.*

The Company leases offices at 65 Sprague St. West B, Boston, MA 02136. The office is approximately 6,000 square feet. The term of the lease is for four years, the lease is currently in its third year of the lease agreement.

## **8) Officers, Directors, and Control Person**

*The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.*

- A. Names of Officers, Directors, and Control Persons.** In responding to this item, please provide the name of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement:

Robert Segersten, President, Treasurer and Director - (73 years of age)

Business address: 65 Sprague St. West B, Boston, MA 02136

Employment history / Board Memberships & other affiliations:

Robert Segersten, President Treasurer and Director: Mr. Segersten founded Woodbine Optical Corporation in 1991 in order to produce OEM video cameras for the medical marketplace. The company quickly added light sources, video couplers and relay lens to its product offering. Woodbine procured large OEM contracts from companies like Bircher Medical, Olympus, and ConMed. His relationship with Bircher Medical allowed Woodbine the opportunity to acquire the

Solos Endoscopy Video division of Bircher. He successfully merged Solos into Woodbine and renamed the company – Solos Endoscopy capitalizing on the strong brand recognition of Solos. He grew the company to approximately \$3 million in sales, at which time he was approached by EndoImage and sold Solos in 1994. He stayed on as President until 1996. He remained an advisor to the company until he reacquired ownership in 2000. He is a graduate of Bates College and received his law degree from Boston University.

Number, Class & Percentage of Outstanding Shares of the Issuers Securities Beneficially Owned:  
Person Named above owns 8,234,360 shares of Common stock and 453,600 Preferred B Shares as of September 30, 2014<sup>(2)</sup>.

<sup>(2)</sup>On February 14, 2014, Robert Segersten converted 900 Preferred Series B shares into 10,000,000 shares of Common Shares of Solos Endoscopy.

Amanda Segersten, Secretary - (37 years of age)

Business address: 65 Sprague St. West B, Boston, MA 02136

Employment history / Board Memberships & other affiliations:

Amanda Segersten, Secretary: Attended Johnson and Wales University and has been employed by Solos Endoscopy since 2000.

Number, Class & Percentage of Outstanding Shares of the Issuers Securities Beneficially Owned:  
Person Named above owns 3,500,000 shares of Common stock and 16,294 Preferred B Shares as of September 30, 2014<sup>(3)</sup>.

<sup>(3)</sup>On February 9, 2012, Amanda Segersten retired 15,000,000 shares of Common Stock held in her name in exchange for 11,794 Preferred Series B Shares of Solos Endoscopy.

Fred Schiemann, Chief Financial Officer, Director - (62 years of age)

Business address: 65 Sprague St. West B, Boston, MA 02136

Employment history / Board Memberships & other affiliations:

Mr. Schiemann previously served as the Chief Financial Officer of Xtreme Oil & Gas, Inc. Prior to that, he has held CFO positions in several corporations and currently serves as Treasurer of Biz2Biz.com. Mr. Schiemann's educational background includes an undergraduate degree from the University of Illinois, Chicago Circle Campus as well as an MBA in taxation from Golden Gate University, Sacramento campus. During his years of practice, Mr. Schiemann has been involved with many public registrations and structuring of mergers and acquisitions. His current practice includes an emphasis on administration and consulting to small and micro-cap public companies.

Number, Class & Percentage of Outstanding Shares of the Issuers Securities Beneficially Owned:  
Person Named above owns 3,500,000 shares of Common stock and 16,294 Preferred B Shares as of September 30, 2014<sup>(4)</sup>.

<sup>(4)</sup>On February 9, 2012, Fred Schiemann retired 15,000,000 shares of Common Stock held in his name in exchange for 11,794 Preferred Series B Shares of Solos Endoscopy.



**B.** Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

**C.** Beneficial Shareholders. provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. if any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the residents agents of the corporate shareholders.

<b><i>Name &amp; Address</i></b>	<b><i>Number of Beneficially Owned Common Shares</i></b>
Name: Robert Segersten Title: President Address: 65 Sprague St. West B Boston, MA 02136	8,234,360 Common shares 453,600 Preferred B Shares

## 9) Third Party Providers

*Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matter relating to operations, business development and disclosure:*

### Legal Counsel

Brian F. Faulkner, A Professional Law Corporation  
27127 Calle Arroyo, San Juan Capistrano, CA 92675  
(949) 249-1361  
BriFFaulk@aol.com

### Accountant or Auditor

Fred Schiemann  
429 W. Plumb Lane  
Reno Nevada 89509  
(775) 324-2012  
fschiemann@yahoo.com

### Other Advisor: Business & Marketing Consultant

Boost Marketing LLC  
PO Box 770302  
Winter Garden, FL 34777  
(321) 236-0240  
info@boostmarketingnow.com

## 10) Issuer Certification

*The issuer shall include certifications but the chief executive officer and chief financial officer of the issuer (or any other person with different title, but having the same responsibilities).*


*I, Robert Segersten, certify that:*

*1. I have reviewed this Quarterly Disclosure Statement of Solos Endoscopy, Inc.;*

*2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and*

*3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.*

Date:



Signature

Title: President